3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 4
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
3
Giant Cell Tumor of Bone
2
Prostatic Neoplasms
1
Osteoporotic Fractures
1
Osteoporosis
1
Neoplasm Metastasis
1
Musculoskeletal Pain
1
Bone Diseases
1
Arthralgia
1
Interventions
Zoledronic Acid
5
Bevacizumab
3
exemestane
2
Therapeutics
2
Standard of Care
2
Pamidronate
2
Oxaliplatin
2
Misoprostol
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ibandronic Acid
2
Fulvestrant
2
Fluorouracil
2
Cetuximab
2
Capecitabine
2
vandetanib
1
palbociclib
1
liposomal doxorubicin
1
huaier
1
eribulin
1
enzalutamide
1
darolutamide
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Vindesine
1
Trastuzumab
1
Sugars
1
Stents
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasm Metastasis
×
Denosumab
×
Clear all
NCT02721433
2020-12-02
REaCT-BTA
Ottawa Hospital Research Institute
Phase 4
Completed
263 enrolled